BASH-004

BASH-004 is a preclinical-stage small molecule drug candidate being developed by Bash Biotech (also known as Bash Today) for the treatment of Parkinson's Disease. The compound is part of a pipeline focused on restoring mitochondrial health through the promotion of mitophagy—the selective degradation of damaged or dysfunctional mitochondria. Mitochondrial dysfunction is a key driver of neurodegeneration in Parkinson's Disease, and BASH-004 is designed to facilitate the clearance of these defective organelles to maintain neuronal homeostasis and prevent cell death. While the specific molecular target of BASH-004 has not been publicly disclosed, the developer's platform primarily utilizes small molecule inhibitors of deubiquitinating enzymes (DUBs), such as USP30, to stimulate the mitophagy pathway.